Pharmaceutical Executive-05-01-2018

In its 12th annual feature, Pharm Exec builds on the revamped approach it introduced last year in spotlighting notable biopharma brands, profiling a new round of products that are making waves in five key areas in healthcare and R&D.

Pair of EU meetings, while well-meant, offered little action and beg the question-what’s the true merit in working together?

Pharm Exec interviews the FDA commissioner, who is building support by combating opioid abuse and advancing innovation.

Meeting the stringent cloud compliance and regulatory requirements in pharma. 

Amid new efforts to inspire more physicians to engage their patients about clinical research, turning that vision into tangible gains in trial participation remains tricky.

A former biology major, biotech investment banker, and venture capitalist, Tim Sullivan brings that sought-after melding of business and scientific perspectives to his role as chief financial officer for Apellis, a clinical-stage drug company hopeful of ushering in novel protein inhibitors form autoimmune disease.

With digitalization enabling patient engagement with their own health experience more than ever before, two critical elements will steer pharma’s advertising path.

Overcoming the challenges of digital brand management will involve choices in spending and channels.

How “patient influencers” look beyond price to help the industry evaluate newly-launched brands.

Charting the course that has led to payer vertical integration and what it may mean for pharma manufacturers.

It’s just as hard to make treatments look good to physicians as it is patients-but communicating through entertainment can be done.

Away from the glare of publicity, a tranche of bold reforms in Canada, aimed at harmonizing the national health system and delivering value for money, are fast nearing completion.

Click the title above to open the Pharmaceutical Executive May 2018 issue in an interactive PDF format.